50216 Federal Register / Vol. 74, No. 188 / Wednesday, September 30, 2009 / Notices 

This technology involves the 

generation of novel chemoattractant 

toxins that deplete the T regulatory cells 

(Treg) or other immunosuppressive or 

hyperactivated cells locally. Treg 

controls activation of immune responses 

by suppressing the induction of 

adaptive immune responses, 

particularly T cell responses. 

Immunosuppressive cells such as tumor 

infiltrating macrophages, regulatory T 

cells, regulatory B cells, or NKT and 

other cells down regulate antitumor 

immune responses. The chemoattractant 

toxins consist of a toxin moiety fused 

with a chemokine receptor ligand, such 

as chemokines and various 

chemoattractants, that enables specific 

targeting and delivery to the regulatory 

cells. This technology is advantageous 

over the more harmful antibodies and 

chemicals that are currently used for the 

systemic depletion of regulatory cells. 

The current technology can be used 

therapeutically in a variety of ways. 

They can be used together with vaccines 

to increase efficacy of the vaccine for 

the treatment of cancer, and can be used 

to locally deplete Treg, Bregs, or other 

immunosuppressive cells to induce 

cytolytic cell responses at the tumor site 

or to eliminate chronic infectious 

diseases such as HIV and tuberculosis. 

Applications: 

• New chemoattractant based toxins 

targeted towards Treg cells. 

• New chemoattractant based toxins 

targeted towards immunosuppressive B 

cells, NKT and macrophages. 

• New chemoattractant based toxins 

targeted towards local depletion of 

hyperactivated CD4 T cells to treat 

autoimmune diseases. 

• Chemoattractant based toxins 

depleting Treg cells or other 

immunosuppressive cells causing 

enhanced vaccine immune responses. 

• Novel immunotherapy by 

increasing vaccine efficacy against 

cancer and infectious diseases. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Market: 

• The technology platform involving 

novel chemo-attractant based toxins can 

be used to improve vaccine immune 

responses. 

• The technology platform has an 

additional market in treating several 

other clinical problems such as 

autoimmune diseases. 

Inventors: Arya Biragyn (NIA), Dolgor 

Bataar (NIA), et al. 

Related Publications: 

1. D Baatar, P Olkhanud, D Newton, 

K Sumitomo, A Biragyn. CCR4- 

expressing T cell tumors can be 

specifically controlled via delivery of 

toxins to chemokine receptors. J 

Immunol. 2007 Aug 1;179(3):1996– 

2004. 

2. D Baatar, P Olkhanud, K Sumitomo, 

D Taub, R Gress, A Biragyn. Human 

peripheral blood T regulatory cells 

(Tregs), functionally primed CCR4+ 

Tregs and unprimed CCR4- Tregs, 

regulate effector T cells using FasL. J 

Immunol. 2007 Apr 15;178(8):4891–900. 

3. M Coscia, A Biragyn. Cancer 

immunotherapy with chemoattractant 

peptides. Semin Cancer Biol. 2004 Jun; 

14(3):209–218. 

4. R Schiavo et al. Chemokine 

receptor targeting efficiently directs 

antigens to MHC class I pathways and 

elicits antigen-specific CD8+ T-cell 

responses. Blood 2006 Jun 15; 

107(12):4597–4605. 

Patent Status: U.S. Patent Application 

No. 11/992,880 filed 28 Mar 2008 (HHS 

Reference No. E–027–2005/0–US–06) 

Licensing Status: Available for 

licensing. 

Licensing Contact: Patrick P. McCue, 

PhD; 301–435–5560; 

mccuepat@mail.nih.gov. 

Collaborative Research Opportunity: 

The Immunotherapeutics Unit, National 

Institute on Aging, is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Chemotoxin technology 

for clinical use or as a laboratory tool for 

depletion of cells. Please contact Nicole 

Darack, PhD at 301–435–3101 or 

darackn@mail.nih.gov for more 

information. 

Novel Agents Exhibiting Cytotoxicity 

Against Human Tumor Cell Lines 

Description of Invention: Researchers 

at the National Cancer Institute have 

developed novel agents that inhibit the 

growth of several human tumor cell 

lines. The new compounds are phenyl 

maleimides, some of which show 

cytotoxicity against human liver cancer 

cells in vitro in the low micromolar 

range. 

Applications: 

• Therapeutics for treating a broad 

range of cancers. 

• Use as pharmacologic probes for 

specific biochemical pathways. 

Advantages: 

• Demonstrated selective inhibition 

for cancer cells vs. untransformed cells 

in vitro and in vivo. 

• Potent growth inhibition of several 

human tumor cell lines. 

Development Status: Pre-clinical stage 

of development. 

Market: Cancer therapeutics. 

Inventors: Christophr J. Michejda and 

Wei Yao (NCI) et al.; Terrence R. Burke 

Jr. (NCI). 

Relevant Publication: S Kar, M Wang, 

W Yao, CJ Michejda, BI Carr. PM–20, a 

novel inhibitor of Cdc25A, induces 

extracellular signal-regulated kinase 1/2 

phosphorylation and inhibits 

hepatocellular carcinoma growth in 

vitro and in vivo. Mol Cancer Ther. 

2006 Jun; 5(6):1511–1519. 

Patent Status: U.S. Patent No. 

7,504,430 issued 17 Mar 2009 (HHS 

Reference No. E–110–2004/0–US–06). 

Licensing Status: Available for 

licensing. 

Licensing Contact: Patrick P. McCue, 

PhD; 301–435–5560; 

mccuepat@mail.nih.gov. 

Dated: September 21, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–23590 Filed 9–29–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Biomedical 

Imaging and Bioengineering; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Biomedical Imaging and Bioengineering 

Special Emphasis Panel. 

Date: November 19, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, 7400 Wisconsin 

Avenue, Bethesda, MD 20814. 

Contact Person: John K. Hayes, PhD, 

Scientific Review Officer, 6707 Democracy 

Boulevard, Suite 959, Democracy Two, 

Bethesda, MD 20892, 301–451–3398, 

hayesj@mail.nih.gov. 


CPrice-Sewell on DSKGBLS3C1PROD with NOTICES
Federal Register / Vol. 74, No. 188 / Wednesday, September 30, 2009 / Notices 50217 

Dated: September 24, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23611 Filed 9–29–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the Board 

of Scientific Counselors for Basic 

Sciences National Cancer Institute. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), Title 5 U.S.C., as amended 

for the review, discussion, and 

evaluation of individual intramural 

programs and projects conducted by the 

National Cancer Institute, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors for Basic Sciences National 

Cancer Institute. 

Date: November 10, 2009. 

Time: 9 a.m. to 2:15 p.m. 

Agenda: To review and evaluate personal 

qualifications and performance, and 

competence of individual investigators. 

Place: National Institutes of Health, 

National Cancer Institute, 9000 Rockville 

Pike, Building 31, Conference Room 6, 

Bethesda, MD 20892. 

Contact Person: Florence E. Farber, PhD, 

Executive Secretary, Office of the Director, 

National Cancer Institute, National Institutes 

of Health, 6116 Executive Boulevard, Room 

2205, Bethesda, MD 20892, 301–496–7628, 

ff6p@nih.gov. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

Information is also available on the 

Institute’s/Center’s home page: http:// 

deainfo.nci.nih.gov/advisory/bsc/bs/bs.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 25, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23588 Filed 9–29–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Microbiology and Infectious 

Diseases Biological Resource Repository. 

Date: October 13, 2009. 

Time: 12 p.m. to 5 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Rockledge 6700, 6700B Rockledge Drive, 

Bethesda, MD 20817. 

Contact Person: Lynn Rust, PhD, Scientific 

Review Officer, Scientific Review Program, 

Division of Extramural Activities, NIAID/ 

NIH/DHHS, 6700B Rockledge Drive, MSC 

7616, Bethesda, MD 20892, 301–402–3938, 

lr228v@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 24, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23617 Filed 9–29–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Allergy, Immunology, 

and Transplantation Research Committee; 

Allergy, Immunology & Transplantation 

Research Review Committee. 

Date: October 15, 2009. 

Time: 8:30 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Chicago, 151 Wacker 

Drive, Chicago, IL 60601. 

Contact Person: Katrin Eichelberg, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIAID/NIH/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892, 301–496– 

0818, keichelberg@niaid.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 24, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–23615 Filed 9–29–09; 8:45 am] 

BILLING CODE 4140–01–P 


CPrice-Sewell on DSKGBLS3C1PROD with NOTICES